Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a TurnaroundZacks Investment Research · Oct 13, 2026 
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare ConferenceGlobeNewsWire · Sep 14, 2026 
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal CancerGlobeNewsWire · Sep 10, 2026 
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For ThursdayBenzinga · Aug 6, 2026 
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More247 Wallst · Aug 6, 2026Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.90 | -$1.92 | Miss |
| May 6, 2026 | -$2.78 | -$1.10 | Beat |
| Mar 12, 2026 | -$2.15 | -$7.68 | Miss |
| Nov 12, 2025 | -$2.81 | -$2.13 | Beat |
| Aug 12, 2025 | -$3.80 | -$2.89 | Beat |
| May 13, 2025 | -$3.60 | -$3.60 | Beat |
